Heart Device Fails to Ease Angina in Trial
Adults with chest pain and open arteries saw no symptom or blood-flow gain from a coronary sinus reducer versus sham.
Updated on Nov. 4, 2026 in Heart Disease

A coronary sinus reducer did not improve blood flow function, angina symptoms, or quality of life compared with a sham procedure in a small randomized trial of patients with refractory angina and no blocked coronary arteries. The device was found to be safe and feasible, and the findings apply to adults with coronary microvascular dysfunction who remain symptomatic despite treatment.
Why it matters
Many people with chest pain have arteries that look open on angiography yet still experience angina from impaired microvascular blood flow, and this trial tested whether a newer device could relieve those symptoms. The negative result tempers early enthusiasm for reducer therapies in this group and underscores the need for controlled evidence before wider adoption.
This randomized, sham-controlled trial enrolled 54 patients with refractory angina and coronary microvascular dysfunction but no obstructed arteries, and the primary endpoint showed no difference in perfusion reserve between groups at 6 months (P = .72). Because the study was small, single-center and investigator-initiated, its findings are preliminary and additional studies are needed.
The players
Shockwave Medical
Shockwave Medical is a medical device company that develops vascular and coronary intervention technologies, and it manufactures the Shockwave Reducer tested in this trial.
Imperial College London
Imperial College London is a leading British research university whose cardiology researchers contribute to clinical trials in coronary and microvascular heart disease.
Royal Brompton Hospital
Royal Brompton Hospital is a London specialist center for heart and lung disease that conducts cardiovascular research and treats complex angina patients.
The details
The coronary sinus reducer is a device implanted in the coronary sinus, the vein that drains blood from the heart muscle, with the aim of altering pressure in the coronary circulation to improve blood flow to the heart. In REMEDY-PILOT, patients were randomly assigned to receive either the reducer (Shockwave Reducer, Shockwave Medical) or a sham procedure. The treated group showed no improvement in microvascular function, daily angina frequency, or the six Seattle Angina Questionnaire domains compared with controls, and the only device-related adverse event was a case of tamponade in the reducer group.
Timeline
Primary endpoint perfusion reserve was measured at 6 months after the procedure.
REMEDY-PILOT results were presented at TCT 2026.
Health Landscape
Sham-controlled trials such as ORBITA have repeatedly shown that procedures can fail to beat placebo for angina, and this trial applies that scrutiny to devices aimed at coronary microvascular dysfunction. The result places reducer therapy among promising but unproven options for patients who remain symptomatic despite medical treatment.
If you have ongoing chest pain or angina even though tests show open coronary arteries, it is worth raising coronary microvascular dysfunction with your cardiologist and asking whether it has been evaluated. Because this trial did not show symptom benefit from a reducer, treatment decisions for this condition should remain a conversation with your physician rather than a reason to seek the device on your own.
The takeaway
Angina with unobstructed arteries is real and can be disabling, but this small trial found that a coronary sinus reducer did not outperform a sham procedure. Track your symptoms and discuss any new treatment option with your doctor before pursuing it.
Further reading
For more background on the conditions behind this research, explore our Heart Disease coverage.
Source note: This article includes information reported by Healio.


